The folks over at Jazz Pharmaceuticals aren’t too happy right now. The Food and Drug Administration has denied approval for JZP-6, or Xyrem, to treat fibromyalgia. Currently Xyrem is used to treat narcolepsy and cataplexy. Due to the cost, no further clinical trials are scheduled.
Although Xyrem was effective in treating fibromyalgia, the FDA concluded that the drug was too risky. Its main ingredient is sodium oxybate, or GHB, which is more commonly used as a date rape drug. Despite this, Jazz Pharmaceuticals’ stocks rose 4 percent Monday.
Good call, FDA. GHB could probably treat anything considering it causes the person to black out…but anyway…
In the United States, 2 percent of the population suffers from fibromyalgia. According to Mayo Clinic, “Fibromyalgia is a chronic condition characterized by widespread pain in your muscles, ligaments and tendons, as well as fatigue and multiple tender points — places on your body where slight pressure causes pain.”
Xyrem is currently being used to treat narcolepsy, but what is that exactly?
Mayo Clinic explains the condition:
Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep. People with narcolepsy often find it difficult to stay awake for long periods of time, regardless of the circumstances. Narcolepsy can cause serious disruptions in your daily routine. Contrary to what some people believe, narcolepsy isn’t related to depression, seizure disorders, fainting, simple lack of sleep or other conditions that may cause abnormal sleep patterns. Narcolepsy is a chronic condition for which there’s no cure.